ESMO 2022: Highlights on TILs versus ipilimumab in patients with advanced melanoma: The phase 3 study
Share.
About Author
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
